In-Vitro Lung Model Market Report 2026

The in-vitro lung model market size has grown exponentially in recent years. It will grow from $0.54 billion in 2025 to $0.65 billion in 2026 at a compound annual growth rate (CAGR) of 21%. The growth in the historic period can be attributed to limitations of animal models in respiratory research, longstanding use of two-dimensional lung cell cultures, increasing respiratory disease research activity, growth in academic lung biology research, early adoption of organoid-based research methods.

The in-vitro lung model market size is expected to see rapid growth in the next few years. It will grow to $1.29 billion in 2030 at a compound annual growth rate (CAGR) of 18.6%. The growth in the forecast period can be attributed to rising demand for predictive preclinical lung models, increasing focus on reducing animal testing, expansion of respiratory drug development pipelines, growing investment in advanced in-vitro research tools, demand for more physiologically relevant lung disease models. Major trends in the forecast period include increasing adoption of three-dimensional lung models in drug research, growing use of lung-on-a-chip platforms for disease modeling, rising preference for human-relevant in-vitro lung testing systems, expansion of in-vitro lung models in toxicology and safety studies, greater integration of in-vitro lung models in preclinical research pipelines.

The growing number of clinical studies is expected to drive the growth of the in vitro lung model market in the coming years. Clinical studies are research investigations carried out to assess the safety, efficacy, and outcomes of new medical treatments, drugs, or diagnostic tools in humans. The volume of clinical studies is increasing due to rising healthcare demands, greater need for advanced medical therapies, and ongoing efforts to develop innovative solutions for complex health conditions. The in vitro lung model market supports clinical research by providing controlled systems that facilitate drug screening, toxicity assessment, disease modeling, and the evaluation of lung-specific biological responses. For example, in January 2024, according to ClinicalTrials.gov, a US-based clinical trial registry, there were 477,230 registered clinical trials worldwide by the end of 2023, up from 437,508 trials in 2022. Therefore, the rise in clinical studies is contributing to the growth of the in vitro lung model market.

Major companies operating in the in vitro lung model market are concentrating on the development of advanced three-dimensional (3D) respiratory tissue models to enhance physiological relevance, improve predictive accuracy, and strengthen preclinical testing capabilities. A 3D respiratory tissue model is a laboratory-engineered, three-dimensional structure composed of primary or specialized respiratory cells cultured under conditions that replicate the structure and function of human airway tissues, including mucus secretion, ciliary activity, and barrier integrity. For instance, in April 2023, MatTek Corporation, a US-based biotechnology company, launched EpiNasal, a 3D respiratory tissue model developed from primary human nasal epithelial cells. This model reproduces key features of nasal epithelium such as goblet cells, functional tight junctions, and motile cilia, offering researchers a highly relevant platform to study the effects of pharmaceuticals, chemicals, pathogens, and consumer products on human respiratory tissues.

In July 2024, Tergus Pharma, a US-based end-to-end service provider for topical pharmaceutical products, merged with MedPharm Ltd. for an undisclosed amount. This merger enhances Tergus Pharma’s integrated development and manufacturing capabilities by combining MedPharm’s strengths in formulation development, in vitro performance testing, and human tissue-based delivery models with Tergus’s expertise in commercial manufacturing and serialization. It also expands the company’s capacity to develop and manufacture hormone-based and highly potent drugs through increased GMP capabilities at its Durham, North Carolina facility. MedPharm Ltd. is a UK-based company that provides in vitro models simulating lung and nasal drug-delivery systems.

Major companies operating in the in-vitro lung model market are Thermo Fisher Scientific Inc., Lonza Group AG, PerkinElmer Inc., Charles River Laboratories International Inc., Epithelix, STEMCELL Technologies, American Type Culture Collection (ATCC), BioIVT, InSphero, Emulate Inc., PhoenixBio Co. Ltd., Newcells Biotech, CN Bio Innovations Ltd., Mimetas, Cyfuse Biomedical K.K., 3D Biotek LLC, AlveoliX AG, Hesperos Inc., SynVivo Inc., VITROCELL Systems GmbH.

North America was the largest region in the in-vitro lung model market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the in-vitro lung model market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the in-vitro lung model market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

Tariffs have impacted the in-vitro lung model market by increasing the cost of imported microfluidic components, laboratory instruments, and specialized cell culture materials used in advanced lung model systems. These effects have been most evident in lung-on-a-chip and three-dimensional model segments, particularly in North America and Europe where high-precision components are often sourced internationally. Asia-Pacific markets have experienced procurement delays due to trade dependencies. However, tariffs have encouraged regional manufacturing of research equipment and localized sourcing of consumables, supporting long-term supply chain resilience.

The in-vitro lung model market research report is one of a series of new reports that provides in-vitro lung model market statistics, including in-vitro lung model industry global market size, regional shares, competitors with a in-vitro lung model market share, detailed in-vitro lung model market segments, market trends and opportunities, and any further data you may need to thrive in the in-vitro lung model industry. This in-vitro lung model market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

An in vitro lung model is a laboratory-based scientific system designed to replicate the cellular, structural, and functional characteristics of the human lung under controlled conditions. These models allow researchers to study disease progression, identify biomarkers, and evaluate the effectiveness of treatments. They serve as valuable tools for advancing the understanding of lung biology, supporting therapy development, and improving overall health outcomes.

The main types of in vitro lung models include two-dimensional (2D) models and three-dimensional (3D) models. A 2D model is a simplified representation of lung cells and tissues cultured on a flat surface and is commonly used in basic research and early-stage substance testing. These models are applied across various areas such as drug discovery, toxicology studies, physiological research, three-dimensional (3D) model development, and others, and are utilized by academic research institutes, pharmaceutical and biotechnology companies, and other end users.

The in-vitro lung model market consists of revenue earned by providing services such as customization services, training and education services, medical education, healthcare training, forensic science, repair and maintenance services, and consulting services. The market value includes the value of related goods sold by the service provider or included within the service offering. The In-vitro lung model models market also includes sales of anatomical organ models, muscle models, human skeleton models, anatomical charts, and posters. Values in this market are ‘factory gate’ values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 1-3 business days.